Accumulating evidence that low RASSF6 expression predicates poor prognosis in multiple gastrointestinal tumors, such as gastric cancer, hepatocellular carcinoma, pancreatic ductal adenocarcinoma. This evidence concerns the gene RASSF6 and pancreatic ductal adenocarcinoma.